TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Table of Contents

1 Executive Summary

2 Introduction, Overview & Background

3 Technologies

3.1 Overview & Discussion
3.1.1 Technologies for Discovery of Antigens for TCRs
3.1.2 Technologies for Discovery of TCRs
3.1.3 Allogeneic T-Cell Technologies 
3.1.4 Technologies for Next Generation TCR T-Cells

3.2 Technologies for Discovery of Targets for TCRs
3.2.1 XPRESIDENT
3.2.2 Target Selection for SPEAR T-Cells
3.2.3 Phosphopeptide Library
3.2.4 HTS Platform for Neoantigen Identification
3.2.5 pMHC Target Discovery
3.2.6 EpiTarget Platform
3.2.7 Neoantigen Prediction

3.3 Technologies for TCR Discovery
3.3.1 SPEAR T-Cell Technology
3.3.2 High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
3.3.3 Single Cell Sequencing Platform
3.3.4 TCR-GENErator
3.3.5 HTS TCR Discovery and Sleeping-Beauty Expression System
3.3.6 Natural, High Affinity TCRs (Bellicum)
3.3.7 High-throughput cloning and characterisation of naturally selected TCRs
3.3.8 Natural TCR Library
3.3.9 Natural TCRs from Vaccinated Patients
3.3.10 T-Rx Mammalian TCR Display
3.3.11 VelociT for T-Cell Receptor Discovery
3.3.12 Combinatorial TCR Exchange (CTE)
3.3.13 Immune Repertoire Capture
3.3.14 E-ALPHA Phage Display
3.3.15 TCRL Antibodies
3.3.16 ACTolog
3.3.17 NEO-STIM

3.4 TCR Engineered Allogeneic T-Cells
3.4.1 ACTallo
3.4.2 universal Immune Cell Therapies (uICT)
3.4.3 GammaDelta T-Cells
3.4.4 Universal Donor Stem Cells
3.4.5 ATO Allogeneic T-Cells

3.5 Next Generation Technologies to Improve Safety & Efficacy
3.5.1 ARTEMIS Technology
3.5.2 CID Technology Platform
3.5.3 Custom Cell Engineering Technologies synNotch and Throttle
3.5.4 DEACT Technology
3.5.5 Dominant TCR Technology
3.5.6 RetroNectin and siTCR Vector Technologies
3.5.7 Stem-to-T-Cell Technology
3.5.8 Transmembrane Immunomodulatory Protein (TIP) Technology

4 Pipeline

4.1 Overview & Discussion
4.1.1 Proof-of-concept
4.1.2 Target Selection
4.1.3 T-Cell Sources & Subtypes
4.1.4 Use of Switches & Next Generation Constructs

4.2 Profiles of MAGE-A Specific TCR T-Cells
4.2.1 KITE-718
4.2.2 MAGE-A4c1032 T
4.2.3 MAGE-A10c796 T
4.2.4 TBI-1201

4.3 Profiles of NY-ESO-1 Specific TCR T-Cells
4.3.1 GSK3377794
4.3.2 NYCE T Cells
4.3.3 TBI-1301

4.4 Profiles of AFP Specific TCR T-Cells
4.4.1 AFPc332 T
4.4.2 ET1402L1 CAR T-Cells

4.5 Profiles of PRAME Specific TCR T-Cells
4.5.1 BPX-701
4.5.2 MDG1011
4.5.3 Dual Switch PRAME TCR T-Cells

4.6 Profiles of WT1 Specitic TCR T-Cells
4.6.1 CMD-602
4.6.2 JTCR016
4.6.3 WT1-Specific Transgenic T-Cells

4.7 Profiles of Other Target Specific TCR T-Cells
4.7.1 IMA201
4.7.2 KITE-439
4.7.3 LTC-H1
4.7.4 TC-210
4.7.5 ZI-H04
4.7.6 ZI-T01

4.8 Profiles of Neoantigen Specific TCR T-Cells
4.8.1 IMA101
4.8.2 NEO-PTC-01

5 Manufacturing 

6 Companies

6.1 Company Overview & Discussion
6.1.1 Pure Play TCR T-Cell Companies
6.1.2 Diversified Companies with TCR-T Activities

6.2 Pure Play TCR T-Cell Companies
6.2.1 Adaptimmune Therapeutics
6.2.2 Gadeta
6.2.3 Immatics US
6.2.4 Lion TCR
6.2.5 Tactiva Therapeutics
6.2.6 Zelluna Immunotherapies
6.2.7 TCR2 Therapeutics

6.3 Profiles of Diversified Companies with TCR-T Activities
6.3.1 Adicet Bio
6.3.2 AgenTus Therapeutics
6.3.3 Bellicum Pharmaceuticals
6.3.4 BioNTech
6.3.5 Bluebird bio
6.3.6 Cell Medica
6.3.7 Eureka Therapeutics
6.3.8 GlaxoSmithKline
6.3.9 Intellia Therapeutics
6.3.10 Juno, a Celgene Company
6.3.11 Kite, a Gilead Company
6.3.12 Medigene
6.3.13 Neon Therapeutics
6.3.14 Regeneron Pharmaceuticals
6.3.15 Takara Bio
6.3.16 TC BioPharm
6.3.17 Tmunity Therapeutics
6.3.18 ZIOPHARM Oncology

6.4 Other Companies with TCR-T Activities
6.4.1 Alpine Immune Sciences
6.4.2 Atreca
6.4.3 ImmunoCellular Therapeutics

7 Business Development & Financing
7.1 Role of academia for the TCR-T industry
7.2 Role of Big Pharma & Biotech for TCR-T
7.3 Technology In-Licensing Deals
7.4 Collaborative Arrangements
7.5 Acquisitions of Companies and Assets
7.6 Financing of TCR-T Companies

8 Outlook & Perspectives

9 References